Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”.
Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved.
Now the drug giant has announced that it is anticipating delays to stock of Estradot TTS-75 from April 9, with supplies returning to normal levels within around eight weeks.
“We understand shortages such as these can cause great uncertainty for patients and we are working hard to resolve this matter as quickly as possible. We encourage any patient affected by this shortage to speak with their doctor or pharmacist for information on available options,” the firm said in a statement.
Supplies of Estradot TTS-25, Estradot TTS-50 and Estradot TTS-100 are unaffected.
BioVaxys Technology Corp., the world leader in haptenized antigen vaccines for antiviral and cancers applications, announced today its sponsorship of this year's World Ovarian Cancer Day, a major initiative of the World Ovarian Cancer Coalition, an ...
China Biologic Products Holdings, Inc., a leading fully integrated plasma-based biopharmaceutical company in China, today announced the completion of its merger with CBPO Group Limited, a wholly owned subsidiary of CBPO Holdings Limited , pursuant to ...